比伐卢定对代谢综合征急性ST段抬高心肌梗死患者急诊经皮冠状动脉介入治疗的安全性  

Safety of bivalirudin in primary percutaneous coronary intervention on patients with acute ST-segment elevation myocardial Infarction and metabolic syndrome

作　　者：孙小强[1] 张善春[1] 邢晓春[1] 李广阔[1] 何峰[1] 田凤石[1] SUN Xiaoqiang;ZHANG Shanchun;XING Xiaochun;LI Guangkuo;HE Feng;TIAN Fengshi(The Fourth Central Hospital of Tianjin,Tianjin 300140,China)

机构地区：[1]天津市第四中心医院,天津300140

出　　处：《实用医学杂志》2019年第9期1473-1476,共4页The Journal of Practical Medicine

基　　金：天津市科技计划项目(编号:17ZXMFSY00200)

摘　　要：目的观察比伐卢定对代谢综合征急性ST段抬高心肌梗死(STEMT)患者急诊经皮冠状动脉介入治疗(PCI)的安全性。方法纳入2016年7月至2017年7月代谢综合征STEMT患者92例,根据术中用药情况分为比伐卢定组和肝素组,其中比伐卢定组42例,肝素组50例。记录患者围手术期及术后1年出血事件及心血管不良事件。结果两组主要心血管不良事件发生率无统计学差异(P>0.05),比伐卢定组出血事件发生率低于肝素组(P <0.05)。结论对于代谢综合征STEMT患者应用比伐卢定具有良好的安全性,且与肝素相比具有较低的出血发生率。Objective To observe Safety of bivalirudin in primary percutaneous coronary intervention (P CI) on patients with acute ST-segment elevation myocardial Infarction( STEMI) and metabolic syndrome. Methods From 2016/7 to 2017/7,a total of 92 patients with acute STEMI and metabolic syndrome treated by primary PCI in our hospital were retrospectively studied.The patients were divided in to two groups according to procedural bivalirudin application as bivalirudin group and heparin group. The baseline condition,coronary artery imaging condition,perioperative and 30-day post-operative occurrence of bleeding events and adverse cardiovascular events were compared between two groups. Results There was no significant difference in incidence of adverse cardiovascular events between two groups( P < 0.05),but the total number of cases with occurrence of bleeding events in the bivalirudin group were significant lower than the heparin group. Conclusion With advantage of lower incidence of bleeding and better safety,bivalirudin shows equivalent antithrombotic effect to heparin.

关 键 词：代谢综合征 急性ST段抬高心肌梗死 经皮冠状动脉介入治疗 比伐卢定 

分 类 号：R542.22[医药卫生—心血管疾病]